CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Has Average Price Target of $10.44 According to Brokerages

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report) have received an average rating of “Moderate Buy” from the eleven research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $10.44.

A number of research firms have recently weighed in on CAMP. Wall Street Zen upgraded shares of CAMP4 Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. UBS Group set a $15.00 target price on CAMP4 Therapeutics in a report on Friday, August 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of CAMP4 Therapeutics in a research note on Tuesday, September 29th. Zacks Research upgraded CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th. Finally, Raymond James Financial assumed coverage on CAMP4 Therapeutics in a research note on Friday, October 23rd. They issued a “strong-buy” rating and a $10.00 target price on the stock.

Read Our Latest Report on CAMP

Insider Buying and Selling

In other CAMP4 Therapeutics news, CFO Kelly Gold purchased 10,000 shares of the firm’s stock in a transaction on Monday, August 31st. The shares were purchased at an average cost of $3.96 per share, with a total value of $39,600.00. Following the completion of the purchase, the chief financial officer owned 10,000 shares of the company’s stock, valued at $39,600. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Andrew J. Schwab sold 400,000 shares of the stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the completion of the sale, the director directly owned 2,033,270 shares of the company’s stock, valued at approximately $8,214,410.80. This trade represents a 16.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 21.69% of the stock is currently owned by corporate insiders.

Institutional Trading of CAMP4 Therapeutics

Several hedge funds have recently modified their holdings of the stock. Integral Health Asset Management LLC purchased a new position in shares of CAMP4 Therapeutics in the third quarter valued at $2,000,000. Empowered Funds LLC purchased a new position in shares of CAMP4 Therapeutics during the 3rd quarter valued at $220,000. Landscape Capital Management L.L.C. acquired a new stake in shares of CAMP4 Therapeutics in the third quarter worth $264,000. Bank of America Corp DE bought a new position in CAMP4 Therapeutics in the 2nd quarter valued at $78,000. Finally, Trails Edge Capital Partners LP bought a new stake in CAMP4 Therapeutics in the 2nd quarter valued at approximately $8,446,935.

CAMP4 Therapeutics Price Performance

Shares of NASDAQ CAMP opened at $3.79 on Thursday. CAMP4 Therapeutics has a fifty-two week low of $2.90 and a fifty-two week high of $7.75. The company’s 50 day simple moving average is $3.82 and its 200 day simple moving average is $4.21. The firm has a market capitalization of $237.82 million, a P/E ratio of -1.77 and a beta of 0.28.

CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The Wireless communications provider reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.17). CAMP4 Therapeutics had a negative net margin of 2,276.33% and a negative return on equity of 182.39%. The business had revenue of $1.90 million during the quarter. Sell-side analysts expect that CAMP4 Therapeutics will post -0.82 EPS for the current fiscal year.

About CAMP4 Therapeutics

(Get Free Report)

CAMP4 Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases in which the body produces too little of an essential protein. The company’s research focuses on increasing the expression of selected genes to address these protein deficiencies. Its Regulatory Action on RNA (RAP) platform is designed to identify regulatory RNAs that influence gene expression. CAMP4 uses antisense oligonucleotides to target these RNAs, with the goal of adjusting the activity of disease-related genes.

See Also

Analyst Recommendations for CAMP4 Therapeutics (NASDAQ:CAMP)

Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.